Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 38

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 38
---
 Financing on May 20, 2025. In July 2025, an additional 666,666 common shares were issued for $2 million received (See Note 8).

License
agreement - See Note 3.

Note
5. Stockholders’ equity (deficit):

Capital
stock

The
Company has the authority to issue 400,000,000 shares of capital stock, consisting of 300,000,000 shares of Common Stock and 100,000,000
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.

ATM
Agreement

On
February 14, 2025, the Company filed a shelf registration statement with the SEC to facilitate the issuance of our common stock and entered
into an At The Market Offering Agreement (the “ATM Agreement”) with Rodman & Renshaw LLC under which the Company may
offer and sell shares of its Common Stock, with an aggregate offering amount sold of up to $100,000,000. During the three months ended June 30, 2025, the Company
sold a total of 18,300 shares of its common stock, at a weighted average price of $2.67 for a total proceeds of $47,769, net of costs of $1,032.

On May 19, 2025, Telomir Pharmaceuticals, Inc. (the
“Company”) entered into an agreement to raise $3 million in equity financing through a direct investment by The Bayshore Trust,
an entity affiliated with the Company’s largest shareholder. The transaction was structured as a straight restricted common stock
deal with no warrants. The Company issued 333,333 restricted shares of its common stock, no par value (the “Common Stock”)
at a purchase price of $3.00 per share, representing an 18% premium to the closing share price of the Common Stock of $2.54 on the date
of execution (the “Bayshore Financing”). The Company received the initial payment of $1 million for the Bayshore Financing
on May 20, 2025. In July 2025, an additional 666,666 common shares were issued for $2 million received (See Note 8).

Restricted Stock Units

On May 27, 2025, 400,000 fully vested common shares
were granted for services to the Company’s CEO. The restricted shares were valued at $